IT8224948A0 - Virus vaccinico modificato e metodi per la produzione ed uso del medesimo. - Google Patents

Virus vaccinico modificato e metodi per la produzione ed uso del medesimo.

Info

Publication number
IT8224948A0
IT8224948A0 IT8224948A IT2494882A IT8224948A0 IT 8224948 A0 IT8224948 A0 IT 8224948A0 IT 8224948 A IT8224948 A IT 8224948A IT 2494882 A IT2494882 A IT 2494882A IT 8224948 A0 IT8224948 A0 IT 8224948A0
Authority
IT
Italy
Prior art keywords
production
methods
vaccine virus
modified vaccine
modified
Prior art date
Application number
IT8224948A
Other languages
English (en)
Other versions
IT8224948A1 (it
IT1191150B (it
Inventor
Enzo Paoletti
Dennis Panicali
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Publication of IT8224948A0 publication Critical patent/IT8224948A0/it
Publication of IT8224948A1 publication Critical patent/IT8224948A1/it
Application granted granted Critical
Publication of IT1191150B publication Critical patent/IT1191150B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IT2494882A 1981-12-24 1982-12-23 Virus vaccinico modificato e metodi per la produzione ed uso del medesimo IT1191150B (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/334,456 US4769330A (en) 1981-12-24 1981-12-24 Modified vaccinia virus and methods for making and using the same

Publications (3)

Publication Number Publication Date
IT8224948A0 true IT8224948A0 (it) 1982-12-23
IT8224948A1 IT8224948A1 (it) 1984-06-23
IT1191150B IT1191150B (it) 1988-02-24

Family

ID=23307294

Family Applications (1)

Application Number Title Priority Date Filing Date
IT2494882A IT1191150B (it) 1981-12-24 1982-12-23 Virus vaccinico modificato e metodi per la produzione ed uso del medesimo

Country Status (3)

Country Link
US (1) US4769330A (it)
IT (1) IT1191150B (it)
ZA (1) ZA829386B (it)

Families Citing this family (352)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505941A (en) * 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US7767449B1 (en) 1981-12-24 2010-08-03 Health Research Incorporated Methods using modified vaccinia virus
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5110587A (en) * 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5338683A (en) * 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5174993A (en) * 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5866383A (en) * 1982-11-30 1999-02-02 The United States Of America As Represented By The Department Of Health And Human Services In vitro ligation of foreign DNA into large eukaryotic viruses
US7045313B1 (en) * 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
CA1310924C (en) * 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
FR2604183B1 (fr) * 1986-09-23 1988-12-30 Transgene Sa Sequence d'adn, vecteurs, virus recombinants et procede mettant en oeuvre des virus de la vaccine recombinants capables de se multiplier dans les cellules cho
CA1341245C (en) * 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
WO1989006705A1 (en) * 1988-01-20 1989-07-27 The United States Of America, As Represented By Th Plaque transfer assay for detecting retrovirus and measuring neutralizing antibodies
US6569679B1 (en) 1988-03-21 2003-05-27 Chiron Corporation Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene
US5997859A (en) * 1988-03-21 1999-12-07 Chiron Corporation Method for treating a metastatic carcinoma using a conditionally lethal gene
US5212057A (en) * 1988-10-26 1993-05-18 University Of Florida Biological system for constructing and testing viral vaccines
US5077213A (en) * 1988-11-10 1991-12-31 Shanghai Institute Of Biochemistry, Chinese Academy Of Sciences Recombinant vaccinia virus
DE69033975T2 (de) * 1989-01-23 2002-10-02 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Rekombinanttherapien für Infektionen und hyperproliferative Störungen
US6248333B1 (en) 1990-04-04 2001-06-19 Health Research Inc. Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD)
US5691170A (en) * 1989-04-18 1997-11-25 Therion Biologics Generation of hybrid genes and proteins by virus-mediated recombination
ATE199398T1 (de) * 1989-10-24 2001-03-15 Chiron Corp Sekretion vom mit gamma-interferon signalpeptid gebundenen humänen protein
GB9014950D0 (en) * 1990-07-06 1990-08-29 Univ Glasgow Ehv-4 glycoprotein vaccine
US5674735A (en) * 1990-07-06 1997-10-07 University Court Of The University Of Glasgow DNA encoding the EHV-4 gH or gC glycoprotein
US5989886A (en) * 1991-01-02 1999-11-23 The Johns Hopkins University Method for the inhibition and prevention of viral replication using fusions of a virus protein and a destructive enzyme
WO1992014486A1 (en) 1991-02-22 1992-09-03 THE UNITED STATES OF AMERICA as represented by THE SECRETARY, THE U.S. DEPARTMENT OF COMMERCE Transmission blocking vaccine against malaria
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
DE69229390T2 (de) 1991-08-26 1999-11-11 Immuno Ag, Wien Direkt molekuläre Klonierung eines modifizierten Genoms eines Chordopocken-Virus
US5527700A (en) * 1992-07-10 1996-06-18 The United States Of America As Represented By The Department Of Health And Human Services Target antigens of transmission blocking antibodies for malaria parasites
US5633234A (en) * 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
WO1994023745A1 (en) * 1993-04-09 1994-10-27 The University Of Virginia Patents Foundation 35/31 kda subunit of the entamoeba histolytica adherence lectin
US6296852B1 (en) 1993-04-14 2001-10-02 Commonwealth Scientific And Industrial Research Organisation Recombinant avian adenovirus vector
AU1257495A (en) 1993-11-18 1995-06-06 Chiron Corporation Compositions and methods for utilizing conditionally lethal genes
US5888814A (en) * 1994-06-06 1999-03-30 Chiron Corporation Recombinant host cells encoding TNF proteins
NZ286915A (en) 1995-07-03 1998-03-25 Akzo Nobel Nv Protein with one or more antigenic determinants of eimeria lactate dehydrogenase, its production and use
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US5858373A (en) * 1995-12-01 1999-01-12 Virogenetics Corporation Recombinant poxvirus-feline infectious peritionitis virus, compositions thereof and methods for making and using them
AU2800797A (en) 1996-04-05 1997-10-29 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
EP2298900A1 (en) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
US6544523B1 (en) * 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US6261562B1 (en) 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US7087713B2 (en) * 2000-02-25 2006-08-08 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
AU8692598A (en) 1997-08-04 1999-02-22 Calydon, Inc. A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
ATE374247T1 (de) 1997-10-14 2007-10-15 Darwin Molecular Corp Thymidinkinase mutanten und fusionproteine mit thymidinkinase und guanylatekinase aktivitäten
ATE476508T1 (de) 1997-11-06 2010-08-15 Novartis Vaccines & Diagnostic Neisseriale antigene
AU2010699A (en) 1997-12-24 1999-07-19 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for theiruse
ES2333071T5 (es) 1998-01-14 2015-08-17 Novartis Vaccines And Diagnostics S.R.L. Antígenos de Neisseria meningitidis
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
KR20010041992A (ko) 1998-03-18 2001-05-25 길리스 스티브 폐암의 치료와 진단을 위한 화합물 및 이를 위한 방법
BR9910089A (pt) 1998-05-01 2004-06-08 Chiron Corp Composições e antìgenos de neisseria meningitidis
DE69934885T2 (de) 1998-06-12 2007-11-08 Mount Sinai School Of Medicine Of The City University Of New York Neue methoden und interferon defiziente substrate zur vermehrung von viren
KR20010085348A (ko) 1998-08-07 2001-09-07 추후보정 면역능을 갖는 헤르페스 심플렉스 바이러스 항원 및 이를이용하는 방법
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US6407063B1 (en) 1998-10-02 2002-06-18 Ludwig Institute For Cancer Research Tumor antigens and CTL clones isolated by a novel procedure
EP1117679B9 (en) * 1998-10-02 2010-07-07 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
ATE386804T1 (de) 1998-10-15 2008-03-15 Novartis Vaccines & Diagnostic Gene mit veränderter expression in metastatischen brust- oder dickdarm- krebszellen
KR20100132086A (ko) 1998-12-08 2010-12-16 코릭사 코포레이션 클라미디아 감염을 치료 및 진단하기 위한 조성물 및 이를 포함하는 약제학적 조성물 및 진단 키트
AU2367600A (en) 1998-12-16 2000-07-03 Chiron Corporation Human cyclin-dependent kinase ((hpnqalre))
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6911429B2 (en) * 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6864235B1 (en) * 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
BR0009505A (pt) 1999-04-02 2002-06-11 Corixa Corp Compostos e processos para terapia e diagnóstico de câncer de pulmão
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
WO2000066741A2 (en) 1999-04-30 2000-11-09 Chiron S.P.A. Conserved neisserial antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
US6497883B1 (en) 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
JP2003510370A (ja) * 1999-10-07 2003-03-18 コリクサ コーポレイション Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓの融合タンパク質
ES2306670T3 (es) 1999-10-22 2008-11-16 Sanofi Pasteur Limited Procedimiento de induccion y/o intensificacion de la respuesta inmunitaria frente a antigenos tumorales.
EP2275553B1 (en) 1999-10-29 2015-05-13 Novartis Vaccines and Diagnostics S.r.l. Neisserial antigenic peptides
PT1234031T (pt) 1999-11-30 2017-06-26 Mayo Foundation B7-h1, uma nova molécula imunoregulatória
PT1248646E (pt) * 1999-12-21 2008-03-19 Merial Sas Composições e vacinas contendo antigénio(s) de cryptosporidium parvum e de outro patógeno entérico
PT1248647E (pt) 2000-01-17 2010-11-18 Novartis Vaccines & Diagnostics Srl Vacina de vesícula da membrana externa (omv) compreendendo proteínas de membrana externa de n. meningitidis do serogrupo b
SI1265915T1 (sl) 2000-02-23 2011-02-28 Glaxosmithkline Biolog Sa Nove spojine
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
ATE389020T1 (de) 2000-04-21 2008-03-15 Corixa Corp Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
US7030219B2 (en) * 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
US7094408B2 (en) * 2000-04-28 2006-08-22 The United States Of America As Represented By The Department Of Health And Human Services Immunogenicity using a combination of DNA and vaccinia virus vector vaccines
PT1282702E (pt) * 2000-05-10 2007-02-28 Ludwig Inst Cancer Res Polipéptidos imunogénicos codificados por minigenes mage e suas utilizações
AU2001269695B2 (en) 2000-05-19 2007-02-15 Corixa Corporation Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-based compounds
EP1950297A2 (en) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
JP5139618B2 (ja) 2000-06-20 2013-02-06 コリクサ コーポレイション Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓの融合タンパク質
WO2002000174A2 (en) 2000-06-28 2002-01-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7666586B2 (en) * 2000-06-30 2010-02-23 Aros Applied Biotechnology Aps Gene expression in biological conditions
US20020165192A1 (en) * 2000-09-19 2002-11-07 Kerr William G. Control of NK cell function and survival by modulation of ship activity
US7691821B2 (en) 2001-09-19 2010-04-06 University Of South Florida Inhibition of SHIP to enhance stem cell harvest and transplantation
DK1328297T3 (da) 2000-10-16 2010-02-01 Cytoguide Aps Funktionen af en haptoglobin-hæmoglobin receptor og anvendelser heraf
NZ560966A (en) 2000-10-27 2010-06-25 Novartis Vaccines & Diagnostic Nucleic acids and proteins from streptococcus groups A & B
US20050196755A1 (en) * 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
ATE352040T1 (de) * 2000-11-17 2007-02-15 Univ Rochester In-vitro verfahren zur herstellung und identifizierung von immunglobulin moleküle in eukaryotischen zellen
WO2002056910A1 (en) 2001-01-17 2002-07-25 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20020108132A1 (en) * 2001-02-02 2002-08-08 Avigenics Inc. Production of a monoclonal antibody by a transgenic chicken
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
US7176300B2 (en) * 2001-03-30 2007-02-13 Avigenics, Inc. Avian lysozyme promoter
WO2002079447A2 (en) * 2001-03-30 2002-10-10 Avigenics, Inc. Avian lysozyme promoter
US7541512B2 (en) * 2001-03-30 2009-06-02 Synageva Biopharma Corp. Avians containing a lysozyme promoter transgene
FR2823222B1 (fr) 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
GB0109515D0 (en) * 2001-04-17 2001-06-06 Neg Micon As A method for transporting a set of large longitudinal items, a package system to be used by the method and use of such a package system
WO2002089747A2 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
EP1281767A3 (en) * 2001-07-31 2003-05-28 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of tumors
US7550650B2 (en) * 2001-09-18 2009-06-23 Synageva Biopharma Corp. Production of a transgenic avian by cytoplasmic injection
EP2172552A3 (en) 2001-10-11 2010-07-21 Merck Sharp & Dohme Corp. Recombinant nucleic acids comprising regions of AD6
US7335761B2 (en) * 2001-11-30 2008-02-26 Avigenics, Inc. Avian gene expression controlling regions
US6875588B2 (en) 2001-11-30 2005-04-05 Avigenics, Inc. Ovomucoid promoter and methods of use
US7294507B2 (en) * 2001-11-30 2007-11-13 Avigenics, Inc. Ovomucoid promoters and methods of use
US20100333219A1 (en) * 2001-11-30 2010-12-30 Synageva Biopharma Corp. Methods of protein production using ovomucoid regulatory regions
KR100982204B1 (ko) 2001-12-12 2010-09-14 노바티스 백신즈 앤드 다이아그노스틱스 에스.알.엘. 클라미디아 트라코마티스에 대한 면역화
CA2476755C (en) 2001-12-17 2014-08-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
WO2003070187A2 (en) * 2002-02-15 2003-08-28 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
US7135562B2 (en) 2002-03-14 2006-11-14 University Of Cincinnati Avian iFABP gene expression controlling region
US20040241723A1 (en) * 2002-03-18 2004-12-02 Marquess Foley Leigh Shaw Systems and methods for improving protein and milk production of dairy herds
EP1496939B1 (en) 2002-04-09 2007-08-15 Sanofi Pasteur Limited Modified cea nucleic acid and expression vectors
CA2425021A1 (en) * 2002-04-12 2003-10-12 Sumitomo Electric Industries, Ltd. Control of the ratio of lap to lip
US20060094006A1 (en) * 2002-05-01 2006-05-04 Genoveffa Franchini Immunotherapy regimens in hiv-infected patients
US20030206916A1 (en) * 2002-05-03 2003-11-06 Rush-Presbyterian-St. Luke's Medical Center Immunogenic peptides
CA2492598C (en) 2002-07-18 2013-12-17 University Of Washington Rapid, efficient purification of hsv-specific t-lymphocytes and hsv antigens identified via same
US20070224124A1 (en) * 2002-09-30 2007-09-27 University Of South Florida Novel SH2containing inositol 5'-phosphatase isoform that partners with the Grb2 adapter protein
US7432351B1 (en) 2002-10-04 2008-10-07 Mayo Foundation For Medical Education And Research B7-H1 variants
MXPA05003621A (es) * 2002-10-09 2005-10-19 Rinat Neuroscience Corp Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos.
DK2279746T3 (da) 2002-11-15 2013-11-25 Novartis Vaccines & Diagnostic Overfladeproteiner i neisseria meningitidis
RU2389732C2 (ru) 2003-01-06 2010-05-20 Корикса Корпорейшн Некоторые аминоалкилглюкозаминидфосфатные производные и их применение
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
CN1980571A (zh) * 2003-01-24 2007-06-13 阿维季尼克斯股份有限公司 禽类及禽蛋中表达的外源蛋白质
EP1606419A1 (en) 2003-03-18 2005-12-21 Quantum Genetics Ireland Limited Systems and methods for improving protein and milk production of dairy herds
ES2319424T3 (es) 2003-03-27 2009-05-07 Ottawa Health Research Institute Virus mutantes de la estomatitis vesivular y sus usos.
US7731974B2 (en) * 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
WO2004098634A2 (en) * 2003-04-30 2004-11-18 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Protein arginine n-methyltransferase 2 (prmt-2)
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
MXPA05013879A (es) * 2003-06-18 2006-06-27 Genelux Corp Virus de la vaccinia recombinantes modificados y otros microorganismos, y usos de los mismos.
WO2005007673A2 (en) * 2003-07-03 2005-01-27 Rush University Medical Center Immunogenic peptides
US8562970B2 (en) * 2003-10-08 2013-10-22 Sanofi Pasteur Limited Modified CEA/B7 vector
WO2005049794A2 (en) 2003-11-13 2005-06-02 University Of Georgia Research Foundation, Inc. Methods of characterizing infectious bursal disease virus
US7807646B1 (en) 2003-11-20 2010-10-05 University Of South Florida SHIP-deficiency to increase megakaryocyte progenitor production
US7763592B1 (en) * 2003-11-20 2010-07-27 University Of South Florida SHIP-deficiency to increase megakaryocyte progenitor production
EP1718770B1 (en) 2004-02-19 2011-05-25 The Governors of the University of Alberta Leptin promoter polymorphisms and uses thereof
DK1736541T3 (da) 2004-03-29 2013-05-06 Galpharma Co Ltd Nyt modificeret galectin 9-protein og anvendelse heraf
EP2261672B1 (en) 2004-07-14 2014-09-03 The Regents of The University of California Biomarkers for early detection of ovarian cancer
MX2007000998A (es) * 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
CA2579764A1 (en) 2004-08-10 2006-02-23 Institute For Multiple Myeloma And Bone Cancer Research Methods of regulating differentiation and treating of multiple myeloma
EP2181714A3 (en) 2004-09-22 2010-06-23 GlaxoSmithKline Biologicals S.A. Immunogenic composition for use in vaccination against staphylococcei
SI1810026T1 (en) 2004-10-06 2018-08-31 Mayo Foundation For Medical Education And Research B7-h1 and pd-1 in treatment of renal cell carcinoma
EP2808384B1 (en) 2004-10-08 2017-12-06 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Modulation of replicative fitness by using less frequently used synonymous codons
US20060194740A1 (en) * 2005-02-25 2006-08-31 Ulevitch Richard J NOD1 as an anti-tumor agent
EP1701165A1 (en) 2005-03-07 2006-09-13 Johannes Dr. Coy Therapeutic and diagnostic uses of TKTL1 and inhibitors and activators thereof
SG158145A1 (en) 2005-03-31 2010-01-29 Glaxosmithkline Biolog Sa Vaccines against chlamydial infection
RS51324B (sr) 2005-04-25 2010-12-31 Merial Ltd. Vakcine protiv nipah virusa
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
SI1877426T1 (sl) 2005-04-29 2012-06-29 Glaxosmithkline Biolog Sa Postopek za preprečevanje ali zdravljenje infekcije z M. tuberculosis
CA2610919C (en) 2005-06-17 2013-09-10 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis c virus nucleic acid vaccine
RU2486204C2 (ru) 2005-07-22 2013-06-27 Уай'З Терапьютикс Ко., Лтд. Антитела против сd26 и способы их применения
UA97469C2 (uk) 2005-07-25 2012-02-27 Емерджент Продакт Дівелопмент Сіетл, Елелсі Гуманізована специфічна до cd37 зв'язувальна молекула імуноглобуліну
WO2007016597A2 (en) * 2005-07-29 2007-02-08 The Regents Of The University Of California Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
US20110223197A1 (en) 2005-10-18 2011-09-15 Novartis Vaccines And Diagnostics Inc. Mucosal and Systemic Immunization with Alphavirus Replicon Particles
EP3147296A1 (en) 2005-11-14 2017-03-29 Merial, Inc. Gene therapy for renal failure
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
US7745158B2 (en) * 2005-12-14 2010-06-29 Kimberly-Clark Worldwide, Inc. Detection of secreted aspartyl proteases from Candida species
WO2007082144A2 (en) * 2006-01-05 2007-07-19 Mayo Foundation For Medical Education And Research B7-h1 and survivin in cancer
WO2007082154A2 (en) * 2006-01-05 2007-07-19 Mayo Foundation For Medical Education And Research B7-h1 and b7-h4 in cancer
AU2007239095B2 (en) 2006-01-09 2012-05-03 The Regents Of The University Of California Immunostimulatory combinations for vaccine adjuvants
US9259463B2 (en) 2006-01-16 2016-02-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Chlamydia vaccine
EP2759307B1 (en) 2006-03-29 2016-11-09 Merial Limited Vaccine against Streptococci
JP5524610B2 (ja) 2006-04-07 2014-06-18 ザ リサーチ ファウンデーション オブ ステイト ユニバーシティー オブ ニューヨーク トランスコバラミン受容体ポリペプチド、核酸およびその調節因子、ならびに細胞の増殖の調節ならびにガンおよびコバラミン欠損症の処置に使用する関連方法
WO2007124361A2 (en) * 2006-04-20 2007-11-01 Mayo Foundation For Medical Education And Research Soluble b7-h1
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
ATE522541T1 (de) 2006-06-09 2011-09-15 Novartis Ag Bakterielle adhäsine konformere
MX363905B (es) 2006-06-12 2019-04-08 Aptevo Res & Development Llc Proteinas de union multivalentes monocatenarias con funcion efectora.
CA2663034C (en) 2006-09-15 2016-05-03 Ottawa Health Research Institute Oncolytic rhabdovirus
SI2484375T1 (en) 2006-09-26 2018-08-31 Infectious Disease Research Institute A vaccine composition comprising a synthetic adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8052968B2 (en) 2006-10-16 2011-11-08 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
US8440185B2 (en) * 2006-12-26 2013-05-14 The Johns Hopkins University Compositions and methods for the treatment of immunologic disorders
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
EP2124998B8 (en) * 2006-12-27 2015-05-06 The Johns Hopkins University Methods for detecting inflammation and auto-immune diseases
CA2671570A1 (en) * 2007-01-26 2008-07-31 Synageva Biopharma Corp. Transgene expression in avians
EP2118292B1 (en) 2007-01-30 2011-08-03 Transgene SA Papillomavirus e2 polypeptide used for vaccination
EP2139447A2 (en) * 2007-03-20 2010-01-06 Harold Brem Gm-csf cosmeceutical compositions and methods of use thereof
US20080234194A1 (en) * 2007-03-20 2008-09-25 Harold Brem Growth factor mediated cosmeceuticals and use thereof to enhance skin quality
US20090081639A1 (en) * 2007-05-31 2009-03-26 Phil Hill Assay for sensitivity to chemotherapeutic agents
CA2690627C (en) * 2007-06-15 2014-12-02 Genelux Corporation Microorganisms for imaging and/or treatment of tumors
DK2170384T3 (en) 2007-07-02 2016-07-25 Etubics Corp METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination
EP2514762B1 (en) 2007-07-13 2015-04-08 The Johns Hopkins University B7-DC variants
WO2009111315A2 (en) * 2008-02-29 2009-09-11 Mayo Foundation For Medical Education And Research Methods for reducing granulomatous inflammation
EP3023502A1 (en) 2008-04-10 2016-05-25 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
NZ621443A (en) 2008-04-11 2015-09-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
WO2009137577A2 (en) 2008-05-08 2009-11-12 Merial Limited Leishmania vaccine using sand fly salivary immunogen
NZ591130A (en) 2008-08-25 2012-09-28 Amplimmune Inc Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
MX2011007386A (es) 2009-01-20 2011-08-03 Transgene Sa Icam-1 soluble como un biomarcador para la prediccion de una respuesta terapeutica.
US20100192236A1 (en) * 2009-01-28 2010-07-29 University Of South Carolina Modulation of Delta Opioid Receptor Expression
NZ595290A (en) 2009-03-24 2012-09-28 Transgene Sa Biomarker for monitoring patients
AU2010234849B2 (en) 2009-03-30 2017-06-22 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
MX347997B (es) 2009-04-03 2017-05-22 Merial Ltd Vacunas aviares vectorizadas con el virus de la enfermedad de newcastle.
US20120058493A1 (en) 2009-04-17 2012-03-08 Bruce Acres Biomarker for monitoring patients
US20100284977A1 (en) * 2009-04-28 2010-11-11 University Of South Carolina Expression of Anti-Nociceptive Compounds from Endogenously Regulated Promoters
US20100303795A1 (en) * 2009-05-27 2010-12-02 Soerensen Karina Dalsgaard Marker of prostate cancer
HRP20161585T1 (hr) 2009-06-05 2016-12-30 Infectious Disease Research Institute Sintetski glukopiranozilni lipidi kao adjuvansi i cjepivni pripravci koji ih sadrže
CA2767458A1 (en) 2009-07-10 2011-01-13 Bruce Acres Biomarker for selecting patients and related methods
ES2622087T3 (es) 2009-08-21 2017-07-05 Merial, Inc. Vacuna recombinante contra paramyxovirus aviar y procedimiento de fabricación y utilización de la misma
EP2473523A2 (en) 2009-08-31 2012-07-11 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
WO2011092253A1 (en) 2010-01-27 2011-08-04 Glaxosmithkline Biologicals S.A. Modified tuberculosis antigens
MA34087B1 (fr) 2010-03-12 2013-03-05 Merial Ltd Vaccins recombinants contre le virus de la langue bleue et leurs utilisations
KR20130075732A (ko) 2010-03-30 2013-07-05 마운트 시나이 스쿨 오브 메디슨 인플루엔자 바이러스 백신 및 이의 용도
PL2611460T3 (pl) 2010-08-31 2017-02-28 Merial, Inc. Szczepionki przeciw herpeswirusom przenoszone z pomocą wirusa choroby newcastle
AR083533A1 (es) 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
US20140287931A1 (en) 2011-04-04 2014-09-25 Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
US20140296248A1 (en) 2011-04-04 2014-10-02 Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
CA2832307A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
EP2697368B1 (en) 2011-04-15 2019-06-05 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
US9216213B2 (en) 2011-04-20 2015-12-22 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
CN103945864A (zh) 2011-04-25 2014-07-23 先进生物学实验室股份有限公司 截短的hiv包膜蛋白(env)、其相关方法和组合物
US10221218B2 (en) 2011-05-10 2019-03-05 The Regents Of The University Of California Adenovirus isolated from titi monkeys
US9267112B2 (en) 2011-05-10 2016-02-23 The Regents Of The University Of California Adenovirus isolated from Titi Monkeys
ES2674439T3 (es) 2011-06-01 2018-06-29 Merial, Inc. Administración sin aguja de vacunas contra el VSRRP
MX2013013627A (es) 2011-06-21 2014-04-25 Oncofactor Corp Composiciones y metodos para la terapia y diagnostico de cancer.
WO2013012446A1 (en) 2011-07-20 2013-01-24 Merial Limited Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene
WO2013025274A1 (en) 2011-08-12 2013-02-21 Merial Limited Vacuum -assisted preservation of biological products, in particular of vaccines
AR088028A1 (es) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
CA2846865A1 (en) 2011-08-29 2013-03-07 The Regents Of The University Of California Use of hdl-related molecules to treat and prevent proinflammatory conditions
WO2013033092A2 (en) 2011-09-03 2013-03-07 Boehringer Ingelheim Vetmedica Gmbh Streptococcus suis pilus antigens
ES2953393T3 (es) 2011-09-20 2023-11-10 Icahn School Med Mount Sinai Vacunas contra el virus de la influenza y sus usos
BR112014013276B1 (pt) 2011-11-30 2021-07-27 Merial, Inc. Vetores hvt recombinantes expressando antígenos de patógenos aviários e usos dos mesmos
WO2013083753A2 (en) 2011-12-07 2013-06-13 Institut Pasteur Identification of a swine parecho-like virus and applications
DK2788021T3 (en) 2011-12-09 2017-04-10 Bavarian Nordic As POXVIRUS VECTOR FOR EXPRESSION OF BACTERIAL ANTIGENES CONNECTED TO TETANANOX INFRAGMENT C
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
EP2811981B1 (en) 2012-02-07 2019-05-08 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
US20140087362A1 (en) 2012-03-16 2014-03-27 Aladar A. Szalay Methods for assessing effectiveness and monitoring oncolytic virus treatment
JP6201166B2 (ja) 2012-03-20 2017-09-27 メリアル インコーポレイテッド 変異糖タンパク質ｃを含む組換えウマヘルペスウイルス‐１ワクチン及びその使用
WO2013158265A1 (en) 2012-04-20 2013-10-24 Genelux Corporation Imaging methods for oncolytic virus therapy
SG10201603896RA (en) 2012-05-04 2016-07-28 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
ES2673556T3 (es) 2012-05-16 2018-06-22 Immune Design Corp. Vacunas para el VHS-2
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
WO2014055960A1 (en) 2012-10-05 2014-04-10 Genelux Corporation Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes
ES2929942T3 (es) 2012-12-18 2022-12-05 Icahn School Med Mount Sinai Vacunas contra el virus de la gripe y sus usos
MX360137B (es) 2013-02-21 2018-10-24 Boehringer Ingelheim Vetmedica Gmbh Proteínas h5 del virus de la influenza h5n1 para usarse como un medicamento.
WO2014164697A1 (en) 2013-03-12 2014-10-09 Merial Limited Reverse genetics schmallenberg virus vaccine compositions, and methods of use thereof
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
WO2014144521A1 (en) 2013-03-15 2014-09-18 The Regents Of The University Of California Mitochondrial-derived peptide mots3 regulates metabolism and cell survival
WO2014144844A1 (en) 2013-03-15 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University tRNA DERIVED SMALL RNAs (tsRNAs) INVOLVED IN CELL VIABILITY
EP3711768A1 (en) 2013-04-18 2020-09-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
EP2986717A1 (en) 2013-04-19 2016-02-24 The Regents of The University of California Lone star virus
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US20160129017A1 (en) 2013-07-01 2016-05-12 The Research Foundation for the State University New York Ship inhibition to combat obesity
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
ES2714708T3 (es) 2013-10-01 2019-05-29 Mayo Found Medical Education & Res Procedimientos para el tratamiento de cáncer en pacientes con niveles elevados de Bim
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
EA201691993A1 (ru) 2014-04-03 2017-02-28 Бёрингер Ингельхайм Ветмедика, Инк. Вакцина к вирусу эпидемической диареи свиней
WO2015179654A1 (en) 2014-05-22 2015-11-26 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti b7-h1 antibodies
US20170128461A1 (en) 2014-06-17 2017-05-11 The Research Foundation For The State University Of New York Ship inhibition to induce expression of granulocyte colony stimulating factor in a subject
JP2017521654A (ja) 2014-06-27 2017-08-03 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ ヒトペギウイルス２（ＨＰｇＶ−２）を検出するための組成物および方法
US10517875B2 (en) 2014-07-23 2019-12-31 Mayo Foundation for Medical Engineering and Research Targeting DNA-PKcs and B7-H1 to treat cancer
AU2015343369B2 (en) 2014-11-03 2018-11-22 Georgia Tech Research Corporation Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
ES3049406T3 (en) 2014-12-19 2025-12-16 Broad Inst Inc Methods for profiling the t-cell-receptor repertoire
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
CA2974699A1 (en) 2015-01-23 2016-07-28 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
US20180071380A1 (en) 2015-03-20 2018-03-15 The Regents Of The University Of Michigan Immunogenic compositions for use in vaccination against bordetella
CR20230191A (es) 2015-05-20 2023-07-06 Dana Farber Cancer Inst Inc NEOANTIGENOS COMPARTIDOS (Div. exp 2017-584)
TW202241500A (zh) 2015-06-09 2022-11-01 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
ES3050936T3 (en) 2015-06-23 2025-12-23 Boehringer Ingelheim Vetmedica Gmbh Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof
PT3344289T (pt) 2015-08-31 2020-04-02 Boehringer Ingelheim Vetmedica Gmbh Vacinas de pestivírus para tremores congénitos
WO2017048677A1 (en) 2015-09-16 2017-03-23 Boehringer Ingelheim Vetmedica, Inc. Salmonella choleraesuis-salmonella typhimurium vaccines
CN108367004B (zh) 2015-09-21 2022-09-13 阿帕特夫研究和发展有限公司 Cd3结合多肽
EP3359651A1 (en) 2015-10-05 2018-08-15 THE UNITED STATES OF AMERICA, represented by the S Human rota virus g9p[6]strain and use as a vaccine
US10875923B2 (en) 2015-10-30 2020-12-29 Mayo Foundation For Medical Education And Research Antibodies to B7-H1
WO2017087550A1 (en) 2015-11-16 2017-05-26 Georgia State University Research Foundation, Inc. Tunable vaccine platform against pathogens of the paramyxovirus family
PL3402802T3 (pl) 2016-01-08 2023-06-05 Geovax, Inc. Kompozycje i sposoby generowania odpowiedzi immunologicznej względem antygenu powiązanego z guzem nowotworowym
ES2811523T3 (es) 2016-01-19 2021-03-12 Pfizer Vacunas contra el cáncer
WO2017184590A1 (en) 2016-04-18 2017-10-26 The Broad Institute Inc. Improved hla epitope prediction
KR102392974B1 (ko) 2016-05-16 2022-05-02 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) Tlr 작용제를 함유하는 제제 및 사용 방법
RU2753874C2 (ru) 2016-06-01 2021-08-24 Инфекшес Дизис Рисёрч Инститьют Наноалюмочастицы, содержащие агент, регулирующий размер
US11266734B2 (en) 2016-06-15 2022-03-08 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
CN109715204B (zh) 2016-09-20 2023-08-22 勃林格殷格翰动物保健有限公司 新的ehv插入位点orf70
EA201990718A1 (ru) 2016-09-20 2019-10-31 Векторы аденовируса собачьих
TW201823465A (zh) 2016-09-20 2018-07-01 德商百靈佳殷格翰維美迪加股份有限公司 新穎豬流感疫苗
DK3516064T3 (da) 2016-09-20 2025-07-14 Boehringer Ingelheim Vetmedica Gmbh Nye promotorer
JP6941171B2 (ja) 2016-11-03 2021-09-29 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ ブタパルボウイルスおよびブタ繁殖呼吸障害症候群ウイルスに対するワクチン、ならびにこれらを作製する方法
CN109803678B (zh) 2016-11-03 2023-08-22 勃林格殷格翰动物保健有限公司 抗猪细小病毒的疫苗
CA3044074A1 (en) 2016-11-16 2018-05-24 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
MX2019008974A (es) 2017-01-30 2019-10-09 Boehringer Ingelheim Animal Health Usa Inc Vacunas contra el coronavirus porcino.
EP3606555A4 (en) 2017-04-07 2021-08-04 Icahn School of Medicine at Mount Sinai INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF
JP7610349B2 (ja) 2017-04-22 2025-01-08 イミュノミック セラピューティックス， インコーポレイテッド 改良ｌａｍｐ構築物
BR112019023014A2 (pt) 2017-05-02 2020-05-19 Immunomic Therapeutics Inc constructos de lamp aperfeiçoados compreendendo antígenos de câncer
AU2018300295A1 (en) 2017-07-11 2020-01-23 Pfizer Inc. Immunogenic compositions comprising CEA MUC1 and TERT
CN110869047B (zh) 2017-07-12 2025-01-10 勃林格殷格翰动物保健美国有限公司 塞内卡病毒a免疫原性组合物及其方法
EP4088783A1 (en) 2017-08-01 2022-11-16 Ab Studio Inc. Bispecific antibodies and uses thereof
US11311612B2 (en) 2017-09-19 2022-04-26 Geovax, Inc. Compositions and methods for generating an immune response to treat or prevent malaria
EP3684812A4 (en) 2017-09-21 2021-09-08 Eucure (Beijing) Biopharma Co., Ltd ANTI-CTLA4 ANTIBODIES AND USES THEREOF
TW201923084A (zh) 2017-09-23 2019-06-16 德商百靈佳殷格翰維美迪加股份有限公司 副黏液病毒科(paramyxoviridae)表現系統
JP2020536115A (ja) 2017-10-04 2020-12-10 オプコ ファーマシューティカルズ、エルエルシー 癌の個別化療法に関する物品および方法
WO2019092027A1 (en) 2017-11-09 2019-05-16 Boehringer Ingelheim Vetmedica Gmbh Sapelovirus immunogenic compositions and uses thereof
AU2017440393B2 (en) 2017-11-24 2025-02-20 Eucure (Beijing) Biopharma Co., Ltd Anti-OX40 antibodies and uses thereof
US11912736B2 (en) 2018-02-21 2024-02-27 The University Of Montana Diaryl trehalose compounds and uses thereof
KR20200124713A (ko) 2018-02-23 2020-11-03 베링거잉겔하임베트메디카게엠베하 외인성 펠라인 파라믹소바이러스 유전자를 발현하는 재조합 바이러스 벡터 시스템 및 이로부터 제조된 백신
AU2018409906B2 (en) 2018-02-23 2025-06-05 Eucure (Beijing) Biopharma Co. , Ltd Anti-PD-1 antibodies and uses thereof
WO2019169313A1 (en) 2018-03-02 2019-09-06 The University Of Montana Immunogenic trehalose compounds and uses thereof
JP7245260B2 (ja) 2018-03-19 2023-03-23 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー Ｅｈｖ挿入部位ｕｌ４３
CN111867625B (zh) 2018-03-19 2024-09-17 勃林格殷格翰动物保健有限公司 具有失活ul18和/或ul8的新ehv
KR102905685B1 (ko) 2018-03-26 2025-12-30 베링거 인겔하임 애니멀 헬스 유에스에이 인크. 면역원성 조성물의 제조방법
CA3100004A1 (en) 2018-05-15 2019-11-21 Immunomic Therapeutics, Inc. Improved lamp constructs comprising allergens
EP3810634A4 (en) 2018-06-21 2022-07-27 Icahn School of Medicine at Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
SG11202100510PA (en) 2018-07-20 2021-02-25 Eucure Beijing Biopharma Co Ltd Anti-cd40 antibodies and uses thereof
JP7387743B2 (ja) 2018-09-12 2023-11-28 ユーカー（ベンジン） バイオファーマ カンパニー，リミテッド 抗ｔｎｆｒｓｆ９抗体及びその使用
TW202026010A (zh) 2018-09-20 2020-07-16 德商百靈佳殷格翰維美迪加股份有限公司 抗豬流行性下痢之鼻內載體疫苗
JP7284822B2 (ja) 2018-09-20 2023-05-31 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 改変ｐｅｄｖスパイクタンパク質
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
EP3873500A4 (en) 2018-10-31 2023-01-11 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
EP3873540A4 (en) 2018-10-31 2022-07-27 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
EP3883969A4 (en) 2018-11-19 2022-11-16 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ANTI-PD-1 ANTIBODIES AND USES THEREOF
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
CN113660956B (zh) 2019-01-28 2024-10-29 Ab诊疗公司 双特异性抗体及其用途
AU2020226445B2 (en) 2019-02-18 2025-05-29 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with humanized immunoglobulin locus
US12545718B2 (en) 2019-04-24 2026-02-10 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
KR20220018503A (ko) 2019-05-23 2022-02-15 더 유니버시티 오브 몬타나 Tlr 수용체 리간드에 기반한 백신 애주번트
CN111979203B (zh) * 2019-05-24 2022-08-19 杭州功楚生物科技有限公司 携带cttnbp2nl基因的溶瘤痘苗病毒、构建方法及在制备抗肿瘤药物中的用途
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
CN121203032A (zh) 2019-10-18 2025-12-26 免疫治疗有限公司 包含癌抗原的改良lamp构建物
BR112022009598A2 (pt) 2019-11-18 2022-08-16 Janssen Biotech Inc Vacinas baseadas em calr e jak2 mutantes e uso dos mesmos
EP4100420A1 (en) 2020-02-06 2022-12-14 Boehringer Ingelheim Vetmedica GmbH Polypeptides useful for detecting anti-rhabdovirus antibodies
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
EP4135757A1 (en) 2020-04-13 2023-02-22 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
AU2021283564B2 (en) 2020-06-02 2025-05-29 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with common light chain immunoglobulin locus
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4176087A1 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. A method for determining responsiveness to prostate cancer treatment
JP7737447B2 (ja) 2020-10-05 2025-09-10 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド サーコウイルス科カプシドタンパク質を含む融合タンパク質、及びそれから構成されるキメラウイルス様粒子
JP2023544396A (ja) 2020-10-05 2023-10-23 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー ロタウイルスに対するワクチン接種のために有用な融合タンパク質
AR128992A1 (es) 2022-04-05 2024-07-03 Boehringer Ingelheim Vetmedica Gmbh Composición inmunógena útil para la vacunación contra el rotavirus
WO2023201201A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof
AU2023302376A1 (en) 2022-07-08 2025-01-16 Viromissile, Inc. Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery
WO2025184411A1 (en) 2024-02-27 2025-09-04 Calidi Biotherapeutics (Nevada), Inc. Serum-resistant eev viruses and uses thereof
TW202543672A (zh) 2024-03-27 2025-11-16 丹麥商阿德森多私人有限公司 抗gpc1抗體及其用途
WO2025202359A1 (en) 2024-03-27 2025-10-02 Adcendo Aps Anti-gpc1 antibodies and uses thereof
WO2025223455A1 (en) 2024-04-24 2025-10-30 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-ptk7/b7h3 antibodies and uses thereof

Also Published As

Publication number Publication date
US4769330A (en) 1988-09-06
IT8224948A1 (it) 1984-06-23
IT1191150B (it) 1988-02-24
ZA829386B (en) 1983-09-28

Similar Documents

Publication Publication Date Title
IT8224948A0 (it) Virus vaccinico modificato e metodi per la produzione ed uso del medesimo.
FI830719A7 (fi) Uudet organopolysiloksaanit, niiden valmistusmenetelmät ja näiden organopolysiloksaanien käyttö.
FI871362L (fi) Virusvaccin.
IT8247706A0 (it) Procedimento per la produzione di virus vaccini
IT8022284A0 (it) N-aril-ossazolidinoni e -pirrolidinoni, e procedimenti per la loro preparazione.
FI831457A7 (fi) 1-sulfo-2-atsetidinon-johdannaiset, niiden valmistus ja käyttö.
DE3484991D1 (de) Katzen-leukaemie-virus-impfstoff.
FI854257A7 (fi) Suun kautta annettavat rokotteet.
DK210483D0 (da) Pyrogallolderivater, deres anvendelse og fremgangsmade til fremstilling deraf
FI883828L (fi) Kalender/verksamhetsplan med indexdel foer bevarande.
FI833075A7 (fi) 2-nitro-1,1-eteenidiamiineja, menetelmiä niiden valmistamiseksi sekä niiden käyttö lääkeaineina.
FI823022A7 (fi) Amino-organoaminosilaanit, niiden valmistusmenetelmä ja niiden käyttö.
FI896203A0 (fi) En eller flerskikts inloppslaoda med utvidgad rwglerzon av genomloppsvolym.
ATE5682T1 (de) Veterinaere impfstoffe gegen pasteurellose.
IT8322612A0 (it) Polipeptidi, loro preparazione eloro impiego come medicamenti.
NL189136B (nl) Polymeersuspensie, werkwijze ter bereiding daarvan alsmede toepassing daarvan.
ES511577A0 (es) Procedimiento para la preparacion del heteropolisacarido s-198.
IT8320023A0 (it) Carbacicline, procedimento per laloro preparazione e loro impiegocome medicinali.
DE3763640D1 (de) Erhitzter scintillator.
DE3381376D1 (de) Temperaturempfindliche reassortierende viren und impfstoff gegen pferdeinfluenza.
NL7908512A (nl) Nieuwe azepino1,2,3-lm-beta-carboline derivaten en de bereidingswijze en toepassing daarvan.
IT1203675B (it) Derivato del ditiolano procedimento per produrlo e sua utilizzazione
IT8321041A0 (it) Virus vaccinico modificato e metodi per la produzione ed uso del medesimo.
NL190120B (nl) 2,3-dihydro-4h-1-benzopyran-4-on-0-carbamoyloximen alsmede farmaceutisch preparaat daarvan.
FI875212A7 (fi) Uudet aryylioksi-3-amino-2-propanolit, niiden valmistus ja käyttö.

Legal Events

Date Code Title Description
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19971223